CN117338869A - A Chinese medicinal capsule and its preparation method - Google Patents
A Chinese medicinal capsule and its preparation method Download PDFInfo
- Publication number
- CN117338869A CN117338869A CN202311562921.2A CN202311562921A CN117338869A CN 117338869 A CN117338869 A CN 117338869A CN 202311562921 A CN202311562921 A CN 202311562921A CN 117338869 A CN117338869 A CN 117338869A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- aloe
- traditional chinese
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 67
- 238000002360 preparation method Methods 0.000 title claims abstract description 67
- 239000000284 extract Substances 0.000 claims abstract description 74
- 239000003814 drug Substances 0.000 claims abstract description 49
- 241000425037 Toona sinensis Species 0.000 claims abstract description 31
- 229940069521 aloe extract Drugs 0.000 claims abstract description 25
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 12
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940046009 vitamin E Drugs 0.000 claims abstract description 12
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 12
- 239000011709 vitamin E Substances 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 238000000605 extraction Methods 0.000 claims description 22
- 238000002156 mixing Methods 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 20
- 235000011783 Cedrela sinensis Nutrition 0.000 claims description 19
- 239000000341 volatile oil Substances 0.000 claims description 18
- 229920000858 Cyclodextrin Polymers 0.000 claims description 17
- 239000001116 FEMA 4028 Substances 0.000 claims description 17
- 229960004853 betadex Drugs 0.000 claims description 17
- 238000001914 filtration Methods 0.000 claims description 16
- 238000001256 steam distillation Methods 0.000 claims description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 12
- 238000010298 pulverizing process Methods 0.000 claims description 12
- 241001116389 Aloe Species 0.000 claims description 11
- 235000011399 aloe vera Nutrition 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 10
- 239000000853 adhesive Substances 0.000 claims description 9
- 230000001070 adhesive effect Effects 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 7
- 108091005658 Basic proteases Proteins 0.000 claims description 7
- 229920002261 Corn starch Polymers 0.000 claims description 7
- 239000008120 corn starch Substances 0.000 claims description 7
- 108010007119 flavourzyme Proteins 0.000 claims description 7
- 235000010445 lecithin Nutrition 0.000 claims description 7
- 229940067606 lecithin Drugs 0.000 claims description 7
- 239000000787 lecithin Substances 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- 229920006316 polyvinylpyrrolidine Polymers 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 244000293323 Cosmos caudatus Species 0.000 claims description 3
- 235000005956 Cosmos caudatus Nutrition 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 206010010774 Constipation Diseases 0.000 abstract description 46
- 230000000694 effects Effects 0.000 abstract description 22
- 210000000936 intestine Anatomy 0.000 abstract description 5
- 210000002784 stomach Anatomy 0.000 abstract description 5
- 230000008855 peristalsis Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 230000013872 defecation Effects 0.000 description 13
- 238000002835 absorbance Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 7
- 102000003425 Tyrosinase Human genes 0.000 description 5
- 108060008724 Tyrosinase Proteins 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 230000002550 fecal effect Effects 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 229940125722 laxative agent Drugs 0.000 description 2
- 230000036564 melanin content Effects 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 229960002983 loperamide hydrochloride Drugs 0.000 description 1
- PGYPOBZJRVSMDS-UHFFFAOYSA-N loperamide hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 PGYPOBZJRVSMDS-UHFFFAOYSA-N 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a traditional Chinese medicine capsule and a preparation method thereof, wherein the traditional Chinese medicine capsule comprises the following components: 100 parts of aloe extract, 450-550 parts of costustoot extract, 80-100 parts of Chinese toon extract, 45-55 parts of pearl and 2-3 parts of vitamin E; the traditional Chinese medicine capsule provided by the invention has the advantages that the components are combined in a reasonable relationship and have a specific proportion, the effects of clearing the intestines and defecating, improving the intestines and promoting the peristalsis of the intestines and the stomach are facilitated, and the constipation is treated and the darkness of the skin caused by the constipation can be obviously improved.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine capsule and a preparation method thereof
Background
Constipation refers to the reduction of defecation times, difficulty in defecation and dry feces; the defecation times per week are less than 3 times, and the disease course is more than 6 months. The prevalence rate of chronic constipation for adults in China is 4-6%, and the prevalence rate of chronic constipation for people over 60 years old is 22%. The causes of chronic constipation are numerous, including: reduced daily activity, increased mental stress, insufficient fiber or fluid intake due to unbalanced diet, reduced intestinal peristalsis due to reduced body function, atrophy of intestinal mucosa and intestinal wall fibers, etc. Constipation affects toxin excretion in the body, further leading to dark skin tone, color spots, etc.
In terms of treatment, at present, most Western medicine adopts permeability, irritation and lubricating laxatives (such as lactulose, enema, polyethylene glycol and the like) and secretagogues and prokinetic medicines, but the adverse effects of medicine treatment are more, and long-term administration is easy to generate dependence and influence the absorption of calcium, phosphorus and fat-soluble vitamins, and long-term administration of the irritation laxatives can cause irreversible enteric nerve damage and can not improve the darkness of skin.
Disclosure of Invention
The invention aims to overcome the defects and provide a traditional Chinese medicine capsule which consists of traditional Chinese medicines and traditional Chinese medicine active extracts and a preparation method thereof, and has the characteristics of long-term use safety and ideal effect.
In a first aspect of the invention, a traditional Chinese medicine capsule for treating constipation and improving skin color is provided, wherein the capsule content comprises the following components in parts by weight:
preferably, the composition comprises the following components in weight:
more preferably, the composition comprises the following components in weight:
the preparation method of the aloe extract comprises the following steps:
(1) Dissolving sulfobutyl-beta-cyclodextrin in 35% -40% ethanol to obtain 40-50mg/mL solution as extraction solvent;
(2) Pulverizing Aloe, reflux extracting with 4-5 times of extraction solvent for 2-3 hr, filtering the extractive solution, removing ethanol under reduced pressure, and lyophilizing the filtrate to obtain Aloe extract.
The preparation method of the costustoot extract comprises the following steps:
(1) Pulverizing radix aucklandiae, soaking in 7-10 times of water for 3-5 hr, adding lecithin, and extracting volatile oil by steam distillation for 1-2 hr;
(2) Adding sodium bicarbonate to adjust pH to 8.0-8.5, adding alkaline protease, and continuing steam distillation for 1-2h, and then adding flavourzyme, and continuing steam distillation for 1-2h;
(3) Collecting volatile oil, dissolving the volatile oil in 40-50mg/mL sulfobutyl-beta-cyclodextrin solution, clathrating, and freeze drying to obtain radix aucklandiae extract 1;
(4) Filtering the extractive solution, and lyophilizing to obtain radix aucklandiae extract 2;
(5) Mixing the radix aucklandiae extract 1 and the radix aucklandiae extract 2 to obtain radix aucklandiae extract.
The preparation method of the toona sinensis extract comprises the following steps:
(1) Dissolving sulfobutyl-beta-cyclodextrin in 15% -25% ethanol to obtain 40-50mg/mL solution as extraction solvent;
(2) Pulverizing Toona sinensis, reflux extracting with 5-6 times of extraction solvent for 2-3 hr, filtering the extractive solution, removing ethanol under reduced pressure, and lyophilizing the filtrate to obtain Toona sinensis extract.
Further, in the aloe extract, the weight of the lecithin is 0.01-0.1 times, preferably 0.06 times of the weight of the costustoot; the weight of the alkaline protease is 0.02-0.06 times of the weight of the costustoot, preferably 0.04 times; the weight of the flavourzyme is 0.08-0.15 times of the weight of the costustoot, preferably 0.12 times; the weight of the sulfobutyl-beta-cyclodextrin solution is 1-1.5 times, preferably 1.2 times of the weight of the costustoot.
Furthermore, the traditional Chinese medicine capsule for treating constipation and improving skin color also comprises pharmaceutically acceptable auxiliary materials, wherein the auxiliary materials are preferably corn starch, magnesium stearate, polyvinylpyrrolidone K30 and the like.
Further, a traditional Chinese medicine capsule for treating constipation and improving skin color comprises the following components in parts by weight:
in some embodiments of the present invention, a traditional Chinese medicine capsule for treating constipation and improving skin color, the capsule content is composed of the following components by weight:
in other embodiments of the present invention, a traditional Chinese medicine capsule for treating constipation and improving skin color, the capsule content is composed of the following components by weight:
the second aspect of the invention provides a preparation method of the traditional Chinese medicine capsule for treating constipation and improving skin color.
A preparation method of a traditional Chinese medicine capsule for treating constipation and improving skin color comprises the following steps:
(1) Preparation of the adhesive:
dissolving polyvinylpyrrolidone K30 in water to obtain solution with adhesive concentration of 12-14%, heating to 40deg.C, and keeping;
(2) Premixing and wet granulating:
mixing aloe extract, radix aucklandiae extract, toonae sinensis extract, margarita, vitamin E, and corn starch in wet mixing granulator, stirring, pre-mixing, spraying binder solution under stirring, and wet granulating.
(3) Drying and granulating:
drying at 40-45deg.C, adding the dried granule into a granulator, and sieving with sieve with aperture of 2.0mm;
(4) Total mixing:
adding magnesium stearate into the granules after finishing, and uniformly mixing;
(5) And (3) filling: the granules are filled into capsules.
Compared with the prior art, the invention has the following beneficial effects:
(1) The raw materials are safer; the aloe, the costustoot, the pearl, the toona sinensis, the vitamin E and the like are used as components for treating constipation, so that the raw materials are safe to use; animal tests and crowd tests prove that the capsule can treat constipation, promote defecation of patients, has no toxic or side effect, and improve skin darkness.
(2) The aloe extract, the costustoot extract and the Chinese toon extract are obtained by adopting a specific extraction process, so that effective substances in the aloe extract, the costustoot extract and the Chinese toon extract can be extracted to the greatest extent, constipation can be treated, and meanwhile, skin darkness caused by the constipation can be remarkably improved.
(3) The components in the traditional Chinese medicine capsule for treating constipation and improving skin color are combined in a reasonable relationship and have a specific proportion, so that the traditional Chinese medicine capsule is beneficial to the effects of clearing the bowels, improving the intestinal tracts and promoting the peristalsis of the intestines and the stomach. Aloe, costustoot, pearl, chinese toon and vitamin E are mixed according to the ratio of 2:10:1.8:1:0.05, so that the patient can remove food retention, resolve phlegm heat, clear heat and detoxify while promoting the circulation of intestines and stomach, and can obviously improve the skin darkness caused by constipation while treating constipation.
Detailed Description
The invention discloses a traditional Chinese medicine capsule for treating constipation and improving skin color and a preparation method thereof, and a person skilled in the art can refer to the content of the traditional Chinese medicine capsule and combine related principles of medicine extraction and medicine preparation to properly improve technological parameters. It is expressly noted that all such similar substitutions and modifications will be apparent to those skilled in the art, and are deemed to be included within the scope of the present invention. While the invention has been described with reference to preferred embodiments, it will be apparent to those skilled in the relevant art that variations and modifications can be made in the methods and applications described herein, or in appropriate changes and combinations, without departing from the spirit and scope of the invention.
For a better understanding of the present invention, and not to limit its scope, all numbers expressing quantities, percentages, and other values used in the present application are to be understood as being modified in all instances by the term "about". Each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
The invention is further illustrated by the following examples, which are not intended to limit the invention in any way.
Preparation example 1: radix aucklandiae extract
(1) 500g of costustoot is crushed, 9 times of water is added for soaking for 4 hours, 30g of lecithin is added, and the volatile oil is extracted by a steam distillation method for 1.5 hours.
(2) Sodium bicarbonate was added to adjust the pH to 8.4, alkaline protease was added in an amount of 20g, and after further steam distillation was continued for 1.5 hours, flavourzyme was added in an amount of 60g, and steam distillation was continued for 1.5 hours.
(3) Collecting volatile oil, dissolving the volatile oil in 600g of 45mg/mL sulfobutyl-beta-cyclodextrin solution, clarifying the solution, and freeze-drying to obtain radix aucklandiae extract 1.
(4) Filtering the extractive solution, and lyophilizing to obtain radix aucklandiae extract 2;
(5) Mixing the radix aucklandiae extract 1 and the radix aucklandiae extract 2 to obtain radix aucklandiae extract.
Preparation example 2: radix aucklandiae extract
(1) 500g of costustoot is crushed, 8 times of water is added for soaking for 4 hours, 30g of lecithin is added, and the volatile oil is extracted by a steam distillation method for 1.5 hours.
(2) Sodium bicarbonate was added to adjust the pH to 8.2, alkaline protease was added in an amount of 20g, and after further steam distillation was continued for 1.5 hours, flavourzyme was added in an amount of 60g, and steam distillation was continued for 1.5 hours.
(3) Collecting volatile oil, dissolving the volatile oil in 600g of 50mg/mL sulfobutyl-beta-cyclodextrin solution, clarifying the solution, and freeze-drying to obtain radix aucklandiae extract 1.
(4) Filtering the extractive solution, and lyophilizing to obtain radix aucklandiae extract 2;
(5) Mixing the radix aucklandiae extract 1 and the radix aucklandiae extract 2 to obtain radix aucklandiae extract.
Preparation example 3: radix aucklandiae extract
(1) 500g of costustoot is crushed, 9 times of water is added for soaking for 4 hours, 30g of lecithin is added, and the volatile oil is extracted by a steam distillation method for 1.5 hours.
(2) Sodium bicarbonate was added to adjust the pH to 8.4, alkaline protease was added in an amount of 20g, and after further steam distillation was continued for 1.5 hours, flavourzyme was added in an amount of 60g, and steam distillation was continued for 1.5 hours.
(3) Collecting volatile oil, dissolving the volatile oil in 600g of 30mg/mL sulfobutyl-beta-cyclodextrin solution, clarifying the solution, and freeze-drying to obtain radix aucklandiae extract 1.
(4) Filtering the extractive solution, and lyophilizing to obtain radix aucklandiae extract 2;
(5) Mixing the radix aucklandiae extract 1 and the radix aucklandiae extract 2 to obtain radix aucklandiae extract.
Preparation example 4: radix aucklandiae extract
(1) 500g of costustoot is crushed, 9 times of water is added for soaking for 4 hours, 30g of lecithin is added, and the volatile oil is extracted by a steam distillation method for 1.5 hours.
(2) Sodium bicarbonate was added to adjust the pH to 8.4, alkaline protease was added in an amount of 20g, and after further steam distillation was continued for 1.5 hours, flavourzyme was added in an amount of 60g, and steam distillation was continued for 1.5 hours.
(3) Collecting volatile oil, dissolving the volatile oil in 400g of 45mg/mL sulfobutyl-beta-cyclodextrin solution, and freeze drying to obtain radix aucklandiae extract 1.
(4) Filtering the extractive solution, and lyophilizing to obtain radix aucklandiae extract 2;
(5) Mixing the radix aucklandiae extract 1 and the radix aucklandiae extract 2 to obtain radix aucklandiae extract.
Preparation example 5: aloe extract
(1) Dissolving sulfobutyl-beta-cyclodextrin in 35% ethanol to obtain a solution with the concentration of 45mg/mL as an extraction solvent;
(2) Pulverizing aloe 100g, reflux extracting with 4.5 times of extraction solvent for 2.5 hr, filtering the extractive solution, removing ethanol under reduced pressure, and lyophilizing the filtrate to obtain aloe extract.
Preparation example 6: aloe extract
(1) Dissolving sulfobutyl-beta-cyclodextrin in 30% ethanol to obtain a solution with the concentration of 45mg/mL as an extraction solvent;
(2) Pulverizing aloe 100g, reflux extracting with 4.5 times of extraction solvent for 2.5 hr, filtering the extractive solution, removing ethanol under reduced pressure, and lyophilizing the filtrate to obtain aloe extract.
Preparation example 7: aloe extract
(1) Dissolving sulfobutyl-beta-cyclodextrin in 35% ethanol to obtain a solution with the concentration of 30mg/mL as an extraction solvent;
(2) Pulverizing aloe 100g, reflux extracting with 4.5 times of extraction solvent for 2.5 hr, filtering the extractive solution, removing ethanol under reduced pressure, and lyophilizing the filtrate to obtain aloe extract.
Preparation example 8: cedrela sinensis extract
(1) Dissolving sulfobutyl-beta-cyclodextrin in 20% ethanol to obtain a solution with the concentration of 45mg/mL as an extraction solvent;
(2) Pulverizing Toona sinensis 90g, reflux extracting with 6 times of extraction solvent for 2.5 hr, filtering, removing ethanol under reduced pressure, and lyophilizing the filtrate to obtain Toona sinensis extract.
Preparation example 9: cedrela sinensis extract
(1) Dissolving sulfobutyl-beta-cyclodextrin in 10% ethanol to obtain a solution with the concentration of 45mg/mL as an extraction solvent;
(2) Pulverizing Toona sinensis 90g, reflux extracting with 6 times of extraction solvent for 2.5 hr, filtering, removing ethanol under reduced pressure, and lyophilizing the filtrate to obtain Toona sinensis extract.
Preparation example 10: cedrela sinensis extract
(1) Dissolving sulfobutyl-beta-cyclodextrin in 20% ethanol to obtain 35mg/mL solution as extraction solvent;
(2) Pulverizing Toona sinensis 90g, reflux extracting with 6 times of extraction solvent for 2.5 hr, filtering, removing ethanol under reduced pressure, and lyophilizing the filtrate to obtain Toona sinensis extract.
Examples 1 to 10: traditional Chinese medicine capsule for treating constipation and improving skin color
Composition of the capsule contents
Examples 1-10 the composition of the capsule contents is shown in table 1 below, wherein aloe extract, costustoot extract, cedrela sinensis extract were prepared by different methods, and are specifically shown in table 2.
TABLE 1
TABLE 2
| Examples | Aloe extract | Radix aucklandiae extract | Cedrela sinensis extract |
| Example 1 | Preparation example 1 | Preparation example 5 | Preparation example 8 |
| Example 2 | Preparation example 2 | Preparation example 5 | Preparation example 8 |
| Example 3 | Preparation example 3 | Preparation example 5 | Preparation example 8 |
| Example 4 | Preparation example 4 | Preparation example 5 | Preparation example 8 |
| Example 5 | Preparation example 1 | Preparation example 6 | Preparation example 8 |
| Example 6 | Preparation example 1 | Preparation example 7 | Preparation example 8 |
| Example 7 | Preparation example 1 | Preparation example 5 | Preparation example 9 |
| Example 8 | Preparation example 1 | Preparation example 5 | Preparation example 10 |
| Preparation example 9 | Preparation example 3 | Preparation example 7 | Preparation example 9 |
| Preparation example 10 | Preparation example 4 | Preparation example 6 | Preparation example 10 |
(II) preparation method:
(1) Preparation of the adhesive:
dissolving polyvinylpyrrolidone K30 in water to obtain solution with adhesive concentration of 13%, heating to 40deg.C, and maintaining;
(2) Premixing and wet granulating:
mixing aloe extract, radix aucklandiae extract, toonae sinensis extract, margarita, vitamin E, and corn starch in wet mixing granulator, stirring, pre-mixing, spraying binder solution under stirring, and wet granulating.
(3) Drying and granulating:
drying at 40-45deg.C, adding the dried granule into a granulator, and sieving with sieve with aperture of 2.0mm;
(4) Total mixing:
adding magnesium stearate into the granules after finishing, and uniformly mixing;
(5) And (3) filling: the granules are filled into capsules.
Examples 11-12 Chinese medicinal capsules for treating constipation and improving skin tone
Composition of the capsule contents
The composition of the contents of the capsules of examples 11-12 is shown in Table 3 below, wherein aloe extract was prepared by the method of preparation example 1, costustoot extract was prepared by the method of preparation example 5, and Cedrela sinensis extract was prepared by the method of preparation example 8.
TABLE 3 Table 3
(II) preparation method
As in example 1.
Examples 13 to 16: traditional Chinese medicine capsule for treating constipation and improving skin color
Composition of the capsule contents: as in example 1.
(II) preparation method: step (1) the adhesive was prepared as shown in Table 4, and steps (2) to (5) were the same as in example 1.
TABLE 4 Table 4
Example 17: detecting the difference of the loading quantity:
according to the method for detecting the loading difference of the four general rules '0103 capsules' of the edition 2020 of Chinese pharmacopoeia, the loading difference of the traditional Chinese medicine capsules for treating constipation and improving skin color prepared in example 1-example 15 is shown in Table 5.
TABLE 5
From comparison of the results of example 1 and example 13-example 16, it is clear that the concentration of the adhesive polyvinylpyrrolidone K30 and the temperature of the adhesive during granulation affect the capsule loading difference, and only the traditional Chinese medicine capsule loading difference for treating constipation and improving skin color, which is prepared by the polyvinylpyrrolidone K30 in a specific concentration range (12% -14%) and a specific temperature (40 ℃), can meet the rules of pharmacopoeia.
Example 18: evaluation of constipation effect:
1. test design
Male C57BL/6 mice, weighing 20-30g, 10 in each group, 150 in total. Divided into 14 groups
Wherein 130 mice are filled with the stomach molding drug loperamide hydrochloride with the dosage of 50mg/Kg, and the continuous stomach filling is carried out for 7 days, thus establishing a mouse intestinal constipation model. Another 10 blank groups;
test article: the traditional Chinese medicine capsules for treating constipation and improving skin color prepared in the embodiments 1-12 are 12 groups, and the model control group does not take any medicine; the doses were 2.5g (Chinese medicinal capsule content for treating constipation and improving skin color)/kg (mice), respectively, and the administration was performed once a day for 5 days.
Observing the first defecation time (min) and the weight (g) of the excrement
2. Test results
The test results are shown in Table 6.
TABLE 6
Note that: # P<0.05； ## P<0.01; compared with the model group
* P<0.05； ** P<0.01; compared with the blank control group
★ P<0.05； ★★ P<0.01; compared with the group of the embodiment 1
(1) Compared with the blank control group, the first defecation time of the model group is obviously increased, the weight of excrement is obviously reduced, and the two have very obvious difference (P is less than 0.01), which indicates that the model is successful.
(2) Compared with a model control group, the traditional Chinese medicine capsules for treating constipation and improving skin color prepared in the embodiment 1-2 can obviously reduce the first defecation time and improve the weight of excrement, and have obvious differences (P is less than 0.01); compared with a blank control group, the traditional Chinese medicine capsules for treating constipation and improving skin color prepared in the examples 1-2 are equivalent in the aspects of first defecation time, fecal weight and the like, and have no obvious difference (P is more than 0.05). The traditional Chinese medicine capsules for treating constipation and improving skin color prepared in the embodiment 1-2 are obvious in treatment effect, and after 5 days of treatment, the treatment effect is equivalent to that of a blank control group.
(3) Compared with a model control group, the traditional Chinese medicine capsules for treating constipation and improving skin color prepared in examples 3-8 and examples 11-12 can remarkably reduce the first defecation time and improve the weight of excrement, and have remarkable differences (P is less than 0.01); compared with the blank control group, the traditional Chinese medicine capsules for treating constipation and improving skin color prepared in examples 3-8 and examples 11-12 have obvious differences (P is less than 0.05) in the aspects of first defecation time, fecal weight and the like. The traditional Chinese medicine capsules for treating constipation and improving skin color prepared in examples 3-8 are obvious in treatment effect, but after 5 days of treatment, the treatment effect is obviously different from that of a blank control group (P is less than 0.05).
(4) Compared with a model control group, the traditional Chinese medicine capsules for treating constipation and improving skin color prepared in the examples 9-10 can obviously reduce the first defecation time and improve the fecal weight, and all have obvious differences (P is less than 0.05); compared with a blank control group, the traditional Chinese medicine capsules for treating constipation and improving skin color prepared in examples 9-10 have obvious differences (P is less than 0.01) in the aspects of first defecation time, fecal weight and the like. The traditional Chinese medicine capsules for treating constipation and improving skin color prepared in examples 3-8 have a certain effect, but after 5 days of treatment, the treatment effect is significantly different from that of a blank control group (P is less than 0.01).
(5) Compared with the group of the example 1, the traditional Chinese medicine capsules for treating constipation and improving skin color prepared in the examples 9-10 can reduce the first defecation time and improve the weight of excrement, but all have very obvious differences (P < 0.01), which shows that the traditional Chinese medicine capsules for treating constipation and improving skin color prepared in the examples 9-10 have obviously worse constipation treating effect than the group of the example 1 and very obvious differences (P < 0.01)
Therefore, only the specific proportion of aloe, costustoot, pearl, chinese toon and vitamin E is in a proportion mode of 2:10:1.8:1:0.05, and the aloe, costustoot and Chinese toon are extracted by a specific method, so that the prepared traditional Chinese medicine capsule for treating constipation and improving skin color has the synergistic effect of all the components, the effect of treating constipation is optimal, and the treatment is close to healing (equivalent to that of a blank control group) after 5 days of treatment.
Example 19: evaluation of skin dullness improving Effect
(1) Tyrosinase activity inhibition assay
Taking mouse melanoma B16 cells in logarithmic growth phase at 5×10 4 Each/mL was inoculated into 6-well cell culture plates, 2mL per well, and cultured overnight. The contents of the capsules of examples 1-15 were added to a final volume fraction of 2% respectively, with the untreated group as the cell control group and 2 duplicate wells per group. After 48h incubation, washing 1 with PBS, adding 100. Mu.L of lysate to each well, scraping the collected cells, and centrifuging to collect the supernatant. mu.L of the cell supernatant was taken into a 96-well plate, and 50. Mu.L of a solution of L-dopa was added thereto, and incubated at 37℃for 1 hour, and absorbance was measured at 475nm by a spectrophotometer.
Relative tyrosinase activity (%) = (assay well absorbance value-blank absorbance value)/(cell control absorbance value-blank absorbance value) ×100%.
(2) Melanin synthesis inhibition assay
Taking mouse melanoma B16 cells in logarithmic growth phase, inoculating the cells into a T25 cell culture flask, and culturing overnight. The contents of the capsules of examples 1-15 were added to a final volume fraction of 2% respectively, with the untreated group as the cell control group. After 48h incubation, washing 1 time with PBS, adding 1mL of 1mol/L NaOH solution, scraping the collected cells, placing in a 80℃water bath for 30min, taking the supernatant, adding into a 96-well plate, and measuring the absorbance at 475nm wavelength with a spectrophotometer. .
Relative melanin content (%) = (measured well absorbance value-blank absorbance value)/(cell control absorbance value-blank absorbance value) ×100%.
The tyrosinase activity and melanin synthesis inhibition test results are shown in Table 3, wherein the tyrosinase activity of the control group is 100%, and the melanin content of the control group is 100%.
(3) Test results
The test results are shown in Table 7.
TABLE 7
/>
As can be seen from table 7: the traditional Chinese medicine capsule for treating constipation and improving skin color provided by the embodiments 1-2 can obviously inhibit the activity of relative tyrosinase, reduce the generation of melanin, obviously improve skin darkness, and have synergistic interaction between the components, and if one component or a preparation method of a certain component is absent, the effect is obviously reduced.
Claims (8)
1. A traditional Chinese medicine capsule, which is characterized in that the capsule content comprises the following components in parts by weight:
100 parts of aloe extract, 450-550 parts of costustoot extract, 80-100 parts of Chinese toon extract, 45-55 parts of pearl and 2-3 parts of vitamin E;
the preparation method of the aloe extract comprises the following steps:
(1) Dissolving sulfobutyl-beta-cyclodextrin in 35% -40% ethanol to obtain 40-50mg/mL solution as extraction solvent;
(2) Pulverizing Aloe, reflux-extracting with 4-5 times of extraction solvent for 2-3 hr, filtering the extractive solution, removing ethanol under reduced pressure, and lyophilizing the filtrate to obtain Aloe extract;
the preparation method of the costustoot extract comprises the following steps:
(1) Pulverizing radix aucklandiae, soaking in 7-10 times of water for 3-5 hr, adding lecithin, and extracting volatile oil by steam distillation for 1-2 hr;
(2) Adding sodium bicarbonate to adjust pH to 8.0-8.5, adding alkaline protease, and steam distilling for 1 hr, and adding flavourzyme, and steam distilling for 1 hr;
(3) Collecting volatile oil, dissolving the volatile oil in 40-50mg/mL sulfobutyl-beta-cyclodextrin solution, clathrating, and freeze drying to obtain radix aucklandiae extract 1;
(4) Filtering the extractive solution, and lyophilizing to obtain radix aucklandiae extract 2;
(5) Mixing the radix aucklandiae extract 1 and the radix aucklandiae extract 2 to obtain radix aucklandiae extract;
the preparation method of the toona sinensis extract comprises the following steps:
(1) Dissolving sulfobutyl-beta-cyclodextrin in 15% -25% ethanol to obtain 40-50mg/mL solution as extraction solvent;
(2) Pulverizing Toona sinensis, reflux extracting with 5-6 times of extraction solvent for 2-3 hr, filtering the extractive solution, removing ethanol under reduced pressure, and lyophilizing the filtrate to obtain Toona sinensis extract.
2. The traditional Chinese medicine capsule according to claim 1, wherein the capsule content comprises the following components:
100 parts of aloe extract, 490-505 parts of costustoot extract, 85-95 parts of Chinese toon extract, 49-51 parts of pearl and 2-3 parts of vitamin E.
3. The traditional Chinese medicine capsule according to claim 2, wherein the capsule content comprises the following components:
the aloe extract weight is 100 parts of aloe, the costustoot extract weight is 500 parts of costustoot, the Chinese toon extract weight is 90 parts of Chinese toon, 50 parts of pearl and 2.5 parts of vitamin E.
4. The traditional Chinese medicine capsule according to claim 3, further comprising pharmaceutically acceptable auxiliary materials, wherein the auxiliary materials are preferably corn starch, magnesium stearate and polyvinylpyrrolidone K30.
5. The traditional Chinese medicine capsule according to claim 4, wherein the capsule content consists of the following components:
the aloe extract comprises, by weight, 100 parts of aloe, 450-550 parts of costustoot, 80-100 parts of Chinese toon extract, 45-55 parts of pearl, 2-3 parts of vitamin E, 30-30 parts of polyvinylpyrrolidone K, 180-220 parts of corn starch and 10-20 parts of magnesium stearate.
6. The traditional Chinese medicine capsule according to claim 5, wherein the capsule content consists of the following components:
100 parts of aloe extract, 500 parts of costustoot extract, 90 parts of Chinese toon extract, 50 parts of pearl, 2.5 parts of vitamin E, 30 parts of polyvinylpyrrolidone K24 parts, 200 parts of corn starch and 16 parts of magnesium stearate.
7. A method for preparing a traditional Chinese medicine capsule according to any one of claims 1-5, comprising the steps of:
(1) Preparation of the adhesive:
dissolving polyvinylpyrrolidone K30 in water to obtain solution with adhesive concentration of 12-14%, heating to 40deg.C, and keeping;
(2) Premixing and wet granulating:
mixing aloe extract, radix aucklandiae extract, toonae sinensis extract, margarita, vitamin E and corn starch in a wet mixing granulator, stirring, pre-mixing, spraying binder solution under stirring, and wet granulating;
(3) Drying and granulating: drying at 40-45deg.C, adding the dried granule into a granulator, and sieving with sieve with aperture of 2.0mm;
(4) Total mixing: adding magnesium stearate into the granules after finishing, and uniformly mixing;
(5) And (3) filling: the granules are filled into capsules.
8. The method for preparing a Chinese medicinal capsule according to claim 7, wherein the concentration of the binder in the step (1) is preferably 13%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311562921.2A CN117338869A (en) | 2023-11-22 | 2023-11-22 | A Chinese medicinal capsule and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311562921.2A CN117338869A (en) | 2023-11-22 | 2023-11-22 | A Chinese medicinal capsule and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117338869A true CN117338869A (en) | 2024-01-05 |
Family
ID=89355905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311562921.2A Pending CN117338869A (en) | 2023-11-22 | 2023-11-22 | A Chinese medicinal capsule and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117338869A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1679746A (en) * | 2005-02-05 | 2005-10-12 | 河北君临药业有限公司 | Medicine for treating constipation |
| CN101129318A (en) * | 2006-08-22 | 2008-02-27 | 马青奇 | Method for preparing novel anti-solarization moisture-keeping vanishing cream which contains ostrich purified oil |
| CN105456149A (en) * | 2014-09-07 | 2016-04-06 | 威海贯标信息科技有限公司 | Preparation method of pearl skin beautifying paste |
| CN116211949A (en) * | 2022-05-11 | 2023-06-06 | 河北君临药业有限公司 | Aloe pearl capsule and preparation method thereof |
| CN116763872A (en) * | 2023-07-20 | 2023-09-19 | 河北君临药业有限公司 | Aloe pearl capsule and preparation method thereof |
-
2023
- 2023-11-22 CN CN202311562921.2A patent/CN117338869A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1679746A (en) * | 2005-02-05 | 2005-10-12 | 河北君临药业有限公司 | Medicine for treating constipation |
| CN101129318A (en) * | 2006-08-22 | 2008-02-27 | 马青奇 | Method for preparing novel anti-solarization moisture-keeping vanishing cream which contains ostrich purified oil |
| CN105456149A (en) * | 2014-09-07 | 2016-04-06 | 威海贯标信息科技有限公司 | Preparation method of pearl skin beautifying paste |
| CN116211949A (en) * | 2022-05-11 | 2023-06-06 | 河北君临药业有限公司 | Aloe pearl capsule and preparation method thereof |
| CN116763872A (en) * | 2023-07-20 | 2023-09-19 | 河北君临药业有限公司 | Aloe pearl capsule and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 吕广利;: "中药内服联合中药外敷治疗痤疮的临床观察", 系统医学, vol. 3, no. 13, 31 December 2018 (2018-12-31), pages 146 - 147 * |
| 张淑云;: "芦荟珍珠胶囊外用治疗黄褐斑的疗效观察", 慢性病学杂志, vol. 14, no. 12, 31 December 2013 (2013-12-31), pages 935 - 936 * |
| 王英军;孙英莲;唐炜;徐宏;许荔新;: "芦荟胶囊通便作用的实验研究", 特产研究, no. 02, 31 December 2007 (2007-12-31), pages 36 - 38 * |
| 陆干明, 孙平, 高宏, 何雯, 努尔古丽: "维生素E、芦荟、珍珠霜的含量测定及临床应用", 中国现代应用药学, vol. 21, no. 06, 31 December 2004 (2004-12-31), pages 517 - 519 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674958A (en) | A kind of Chinese medicine composition and its preparation method and application with anti-trioxypurine | |
| KR101898688B1 (en) | Composition for preventing, treating or improving muscle atrophy comprising complex extracts | |
| CN116211949A (en) | Aloe pearl capsule and preparation method thereof | |
| CN110559403B (en) | Traditional Chinese medicine composition for preventing and treating hyperuricemia and preparation method and application thereof | |
| US10653746B2 (en) | Medicament for use in treating gout | |
| CN103127198B (en) | Combined drug for treating piglet's yellow-white dysentery | |
| CN104027428B (en) | Preparation method of traditional Chinese medicine compound and application of traditional Chinese medicine compound in prevention and treatment of senile dementia | |
| KR100601390B1 (en) | Anti-Obesity ingredients from medicinal plants and their composition | |
| CN117338869A (en) | A Chinese medicinal capsule and its preparation method | |
| KR20170062781A (en) | Composition Comprising Black Ginseng Extract having Improving Activity of Cognitive Function | |
| CN102133273A (en) | Traditional Chinese medicine lipid-lowing and aperient capsule and preparation method thereof | |
| CN109044982A (en) | A kind of nauclea officinalis medicinal extract sustained release tablets and preparation method thereof | |
| CN107890528A (en) | A kind of Chinese medicine composition for treating hyperuricemia and preparation method thereof | |
| CN109908202A (en) | A kind of pharmaceutical composition and preparation method thereof for treating hyperuricemia | |
| CN116407582B (en) | Compound preparation for treating RA and multi-organ complications thereof and preparation method thereof | |
| CN117442677B (en) | Pharmaceutical composition for kidney injury and preparation method and application thereof | |
| CN104491011B (en) | A kind of rotavirus for the treatment of causes Chinese medicine composition of baby diarrhea and preparation method thereof | |
| KR102123013B1 (en) | Composition for Preventing or Treating Neuro-degenerative Disease Containing Extract of Angelica gigas Nakai or Mixed Extract of Angelica gigas Nakai and Brassica oleracea var. italica | |
| KR102123014B1 (en) | Healthy Functional Food for Preventing or Improving Neuro-degenerative Disease Containing Extract of Angelica gigas Nakai or Mixed Extract of Angelica gigas Nakai and Brassica oleracea var. italica | |
| JP2618286B2 (en) | Hypotensive yeast preparation and its production method | |
| CN116392527B (en) | Preparation for improving chronic kidney disease | |
| CN116942742B (en) | Uric acid reducing traditional Chinese medicine composition and preparation method thereof | |
| KR102172371B1 (en) | A pharmaceutical composition comprising extract of Aloe, quince and corn silk for preventing or treating obesity | |
| CN107296817B (en) | Use of Poria extract and temmoic acid for protecting muscle | |
| CN107335026B (en) | Medicine for treating focal segmental glomerulosclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |